Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week

R. Ferreiro-Iglesias, A. Jardi, A. Quiroga, I. Baston, J. Gonzalez, J. M. Giraldez, I. Zarra, M. J. Lamas, J. E. Dominguez-Munoz, M. Barreiro-de Acosta

Resultado de la investigación

Idioma originalEnglish
Páginas (desde-hasta)S390-S391
PublicaciónJournal of Crohn's and Colitis
Volumen13
EstadoPublished - mar 2019

Citar esto

Ferreiro-Iglesias, R., Jardi, A., Quiroga, A., Baston, I., Gonzalez, J., Giraldez, J. M., Zarra, I., Lamas, M. J., Dominguez-Munoz, J. E., & Barreiro-de Acosta, M. (2019). Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week. Journal of Crohn's and Colitis, 13, S390-S391.